Surgical Science Sweden AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0014428512
SEK
30.70
-0.26 (-0.84%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Company has a low Debt to Equity ratio (avg) at times

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 56.77% and Operating profit at 44.68%

 
3

Flat results in Dec 25

4

With ROE of 2.59%, it has a fair valuation with a 1.02 Price to Book Value

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 1,607 Million (Small Cap)

stock-summary
P/E

39.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.14

stock-summary
Return on Equity

2.01%

stock-summary
Price to Book

0.38

Revenue and Profits:
Net Sales:
269 Million
(Quarterly Results - Dec 2025)
Net Profit:
33 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.24%
0%
-4.24%
6 Months
-65.52%
0%
-65.52%
1 Year
-76.13%
0%
-76.13%
2 Years
-79.31%
0%
-79.31%
3 Years
-81.21%
0%
-81.21%
4 Years
-84.42%
0%
-84.42%
5 Years
-73.3%
0%
-73.3%

Surgical Science Sweden AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
56.77%
EBIT Growth (5y)
44.68%
EBIT to Interest (avg)
47.45
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
0.20
Tax Ratio
20.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.57%
ROE (avg)
4.01%

Valuation key factors

Factor
Value
P/E Ratio
39
Industry P/E
Price to Book Value
1.02
EV to EBIT
25.80
EV to EBITDA
17.42
EV to Capital Employed
1.02
EV to Sales
3.99
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.95%
ROE (Latest)
2.59%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 2.01% vs 26.00% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 63.24% vs 201.49% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "268.90",
          "val2": "263.60",
          "chgp": "2.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "71.00",
          "val2": "58.80",
          "chgp": "20.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "33.30",
          "val2": "20.40",
          "chgp": "63.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "174.80%",
          "val2": "145.90%",
          "chgp": "2.89%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 12.24% vs 0.14% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -49.24% vs -43.76% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "992.30",
          "val2": "884.10",
          "chgp": "12.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "192.30",
          "val2": "209.90",
          "chgp": "-8.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "5.70",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "66.80",
          "val2": "131.60",
          "chgp": "-49.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "109.80%",
          "val2": "169.00%",
          "chgp": "-5.92%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
268.90
263.60
2.01%
Operating Profit (PBDIT) excl Other Income
71.00
58.80
20.75%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
33.30
20.40
63.24%
Operating Profit Margin (Excl OI)
174.80%
145.90%
2.89%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 2.01% vs 26.00% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 63.24% vs 201.49% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
992.30
884.10
12.24%
Operating Profit (PBDIT) excl Other Income
192.30
209.90
-8.38%
Interest
0.00
5.70
-100.00%
Exceptional Items
0.00
-0.30
100.00%
Consolidate Net Profit
66.80
131.60
-49.24%
Operating Profit Margin (Excl OI)
109.80%
169.00%
-5.92%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 12.24% vs 0.14% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -49.24% vs -43.76% in Dec 2024

stock-summaryCompany CV
About Surgical Science Sweden AB stock-summary
stock-summary
Surgical Science Sweden AB
Pharmaceuticals & Biotechnology
Surgical Science Sweden AB is a Sweden-based company, which provides with virtual reality simulators for evidence based laparoscopic and endoscopic training. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.
Company Coordinates stock-summary
Company Details
Drakegatan 7 A, 3 tr. , GOETEBORG None : 412 50
Registrar Details